Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine
Stringer J, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, Vermund SH. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003, 17: 1659-1665. PMID: 12853748, PMCID: PMC2745973, DOI: 10.1097/00002030-200307250-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBreast FeedingDrug Administration ScheduleFemaleHIV InfectionsHIV SeropositivityHumansInfant, NewbornInfectious Disease Transmission, VerticalLabor, ObstetricNevirapineObstetric Labor ComplicationsPregnancyPregnancy Complications, InfectiousProspective StudiesReverse Transcriptase InhibitorsRisk FactorsTime FactorsConceptsPerinatal HIV transmissionHIV transmissionInfant HIV infection statusNeonatal single-dose nevirapineMaternal drug doseSingle-dose nevirapineHIV infection statusProspective cohort studyPerinatal transmission rateOnset of laborMain outcome measuresMean drug concentrationWeeks of lifeRisk of transmissionNVP levelsNVP prophylaxisNVP syrupObstetrical clinicPerinatal transmissionCohort studyOral doseViral loadPregnant womenPolymerase chain reactionRisk factors